Connor, Clark & Lunn Investment Management Ltd. Astrazeneca PLC Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Astrazeneca PLC stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 17,810 shares of AZN stock, worth $1.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
17,810
Previous 12,788
39.27%
Holding current value
$1.2 Million
Previous $997,000
39.12%
% of portfolio
0.01%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding AZN
# of Institutions
1,359Shares Held
475MCall Options Held
5.39MPut Options Held
3.75M-
Price T Rowe Associates Inc Baltimore, MD62.9MShares$4.24 Billion0.56% of portfolio
-
Primecap Management CO Pasadena, CA42MShares$2.83 Billion2.45% of portfolio
-
Wellington Management Group LLP Boston, MA37.2MShares$2.51 Billion0.52% of portfolio
-
Capital International Investors Los Angeles, CA36.8MShares$2.48 Billion0.57% of portfolio
-
Franklin Resources Inc San Mateo, CA19.1MShares$1.29 Billion0.45% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $209B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...